CA2880742C - Combination therapy for treatment of multiple sclerosis - Google Patents

Combination therapy for treatment of multiple sclerosis Download PDF

Info

Publication number
CA2880742C
CA2880742C CA2880742A CA2880742A CA2880742C CA 2880742 C CA2880742 C CA 2880742C CA 2880742 A CA2880742 A CA 2880742A CA 2880742 A CA2880742 A CA 2880742A CA 2880742 C CA2880742 C CA 2880742C
Authority
CA
Canada
Prior art keywords
dimethylfumarate
fingolimod
pharmaceutical composition
teriflunomide
laquinimod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2880742A
Other languages
English (en)
French (fr)
Other versions
CA2880742A1 (en
Inventor
Theis Terwey
Roland Rupp
Peder M. Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FWP IP ApS
Original Assignee
FWP IP ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FWP IP ApS filed Critical FWP IP ApS
Priority to CA3107367A priority Critical patent/CA3107367A1/en
Publication of CA2880742A1 publication Critical patent/CA2880742A1/en
Application granted granted Critical
Publication of CA2880742C publication Critical patent/CA2880742C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2880742A 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis Active CA2880742C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3107367A CA3107367A1 (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis comprising dimethyl fumarate and teriflunomide

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP12179232.9A EP2692343A1 (en) 2012-08-03 2012-08-03 Combination therapy for treatment of multiple sclerosis
EP12179232.9 2012-08-03
US201261712008P 2012-10-10 2012-10-10
US61/712,008 2012-10-10
EP12187939.9A EP2692344A1 (en) 2012-08-03 2012-10-10 Combination therapy for treatment of Multiple sclerosis
EP12187939.9 2012-10-10
PCT/EP2013/066285 WO2014020156A1 (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3107367A Division CA3107367A1 (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis comprising dimethyl fumarate and teriflunomide

Publications (2)

Publication Number Publication Date
CA2880742A1 CA2880742A1 (en) 2014-02-06
CA2880742C true CA2880742C (en) 2021-03-16

Family

ID=47008405

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2880742A Active CA2880742C (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis
CA3107367A Abandoned CA3107367A1 (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis comprising dimethyl fumarate and teriflunomide

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3107367A Abandoned CA3107367A1 (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis comprising dimethyl fumarate and teriflunomide

Country Status (20)

Country Link
US (2) US20150164849A1 (enExample)
EP (4) EP2692343A1 (enExample)
JP (2) JP2015523407A (enExample)
KR (3) KR20150040338A (enExample)
CN (3) CN104684553A (enExample)
AU (3) AU2013298517A1 (enExample)
CA (2) CA2880742C (enExample)
DK (1) DK2879672T3 (enExample)
EA (1) EA201590166A8 (enExample)
ES (1) ES2674947T3 (enExample)
HR (1) HRP20180939T1 (enExample)
HU (1) HUE038382T2 (enExample)
LT (1) LT2879672T (enExample)
PL (1) PL2879672T3 (enExample)
PT (1) PT2879672T (enExample)
RS (1) RS57567B1 (enExample)
SI (1) SI2879672T1 (enExample)
SM (1) SMT201800380T1 (enExample)
TR (1) TR201808859T4 (enExample)
WO (1) WO2014020156A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011001341A (es) 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA41139B1 (fr) * 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
HUE057865T2 (hu) 2014-12-11 2022-06-28 Actelion Pharmaceuticals Ltd A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend
EP4252847A3 (en) 2016-08-15 2023-11-15 Novartis AG Regimens and methods of treating multiple sclerosis using ofatumumab
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
TR201820976A2 (tr) * 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
JP7794735B2 (ja) * 2019-09-11 2026-01-06 ノバルティス アーゲー 切替え療法によるｒｍｓの治療
US20230099229A1 (en) 2020-03-13 2023-03-30 Reprise Pharmaceuticals, Inc. Methods of treating multiple sclerosis
AR122023A1 (es) * 2020-05-06 2022-08-03 Imcyse Sa Péptidos y métodos para el tratamiento de esclerosis múltiple
CN116672325B (zh) * 2023-06-06 2024-09-03 哈尔滨工业大学 一种包覆中性粒细胞膜的聚芬戈莫德纳米前药的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080227847A1 (en) 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP2564839B1 (en) 2009-01-09 2016-05-11 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
DK2533634T3 (en) 2010-02-12 2016-01-25 Biogen Ma Inc NEURO PROTECTIVE demyelinating diseases
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Also Published As

Publication number Publication date
KR20150040338A (ko) 2015-04-14
US20150164849A1 (en) 2015-06-18
SMT201800380T1 (it) 2018-09-13
EA201590166A8 (ru) 2015-10-30
LT2879672T (lt) 2018-07-10
CN104684553A (zh) 2015-06-03
US20190091190A1 (en) 2019-03-28
EP2879672B1 (en) 2018-04-11
DK2879672T3 (en) 2018-07-30
SI2879672T1 (sl) 2018-10-30
AU2020201290B2 (en) 2021-08-19
HK1211210A1 (en) 2016-05-20
ES2674947T3 (es) 2018-07-05
PL2879672T3 (pl) 2018-10-31
HUE038382T2 (hu) 2018-10-29
EP2879672A1 (en) 2015-06-10
HRP20180939T1 (hr) 2018-12-14
CA2880742A1 (en) 2014-02-06
TR201808859T4 (tr) 2018-07-23
AU2020201290A1 (en) 2020-03-12
CA3107367A1 (en) 2014-02-06
EA201590166A1 (ru) 2015-06-30
AU2013298517A1 (en) 2015-03-05
EP2692344A1 (en) 2014-02-05
PT2879672T (pt) 2018-07-03
EP2692343A1 (en) 2014-02-05
JP2018150375A (ja) 2018-09-27
WO2014020156A1 (en) 2014-02-06
RS57567B1 (sr) 2018-10-31
AU2018201801A1 (en) 2018-04-05
EP3398595A1 (en) 2018-11-07
CN107669668A (zh) 2018-02-09
KR20210147083A (ko) 2021-12-06
AU2018201801B2 (en) 2019-11-21
KR20200142597A (ko) 2020-12-22
CN113288891A (zh) 2021-08-24
JP2015523407A (ja) 2015-08-13

Similar Documents

Publication Publication Date Title
EP2879672B1 (en) Combination therapy for treatment of multiple sclerosis
US20100260755A1 (en) Ibudilast and immunomodulators combination
AU2010242064A2 (en) Treatment of neurodegeneration and neuroinflammation
RS54551B1 (sr) Neuroprotekcija kod demijelinizujućih bolesti
Feagan et al. 943b Induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial
WO2015105757A1 (en) Dimethyl fumarate for treating multiple sclerosis
CA2728514C (en) Paediatric compositions for treating multiple sclerosis
US20210401880A1 (en) Pharmaceutical Composition For Preventing Or Treating Obesity, Containing CYCLO(HIS-PRO) As Active Ingredient
JP6884841B2 (ja) 多発性硬化症を処置するための併用療法
HK1211210B (en) Combination therapy for treatment of multiple sclerosis
UA127031C2 (uk) Комбінована терапія для лікування розсіяного склерозу
TW202513062A (zh) 含有佩瑪貝特（Ｐｅｍａｆｉｂｒａｔｅ）之醫藥
TW201106945A (en) Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
EP1758563A1 (en) Combination therapy with glatiramer acetate and minocycline for the treatment of multiple sclerosis
KR20120089295A (ko) 다발성 경화증을 치료하기 위한 테리플루노마이드 및 글라티라머 아세테이트의 병용 용도
WO2012110946A1 (en) Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate
HK1202253B (en) Combination treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180716

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250203